Ohio State Navbar

Ohio State Trial Tests Novel Two-Drug Combination For Triple Negative Breast Cancers

Dr. Erin Macrae explained how breast cancer researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute (OSUCCC – James) are testing an experimental, two-drug medical therapy for advanced triple negative breast cancers. Approximately 40 patients will enroll in this National Cancer Institute-sponsored phase 2 study nationwide. Triple negative breast cancers represent 15-20 percent of the more than 211,000 women diagnosed with breast cancer annually in the United States. These breast cancers are often more aggressive, occur in younger women and have limited treatment options. In this Ohio State-led trial, breast medical oncologist and principal investigator Macrae will test two new experimental drugs, given in combination, that target specific tumor proteins involved cancer growth and survival. This coverage resulted from a news release distributed by Ohio State University Wexner Medical Center Public Affairs and Media Relations, available online at http://cancer.osu.edu/mediaroom/releases/Pages/triplenegativebreastcancer.aspx